| 1 |
Introna M, Lucchini G, Dander E, et al. Treatment of graft versus host disease with mesenchymal stromal cells: a phase I study on 40 adult and pediatric patients[J].Biol Blood Marrow Transplant, 2014, 20(3):375-381.
|
| 2 |
Hu J, Yu X, Wang Z, et al. Long term effects of the implantation of Wharton’s jelly-derived mesenchymal stem cells from the umbilical cord for newly-onset type 1 diabetes mellitus[J]. Endocr J, 2013, 60(3):347-357.
|
| 3 |
Tan J, Wu W, Xu X, et al. Induction therapy with autologous mesenchymal stem cells in living-related kidney transplants:a randomized controlled trial[J].JAMA, 2012, 307(11):1169-1177.
|
| 4 |
姚志成，刘波.间充质干细胞促进肝再生的研究进展[J].中华肝脏外科手术学电子杂志, 2016, 5(3):198-200.
|
| 5 |
黄守强，彭秀军.间充质干细胞移植治疗眼干燥症的研究进展[J].转化医学杂志, 2015, (5):306-310.
|
| 6 |
Cyranoski D. Korean deaths spark inquiry[J]. Nature, 2010, 468(7323):485.
|
| 7 |
Martin BM, Samy KP, Lowe MC, et al. Dual islet transplantation modeling of the instant blood-mediated inflammatory reaction[J]. Am J Transplant, 2015, 15(5):1241-1252.
|
| 8 |
Bartholomew A, Sturgeon C, Siatskas M, et al. Mesenchymal stem cells suppress lymphocyte proliferation in vitro and prolong skin graft survivalin vivo[J]. Exp Hematol, 2002, 30(1):42-48.
|
| 9 |
Krampera M, Glennie S, Dyson J, et al. Bone marrow mesenchymal stem cells inhibit the response of naive and memory antigen-specific T cells to their cognate peptide[J]. Blood, 2003, 101(9):3722-3729.
|
| 10 |
Le Blanc K, Tammik L, Sundberg B, et al. Mesenchymal stem cells inhibit and stimulate mixed lymphocyte cultures and mitogenic responses independently of the major histocompatibility complex[J]. Scand J Immunol, 2003, 57(1):11-20.
|
| 11 |
Ortiz LA, Gambelli F, Mcbride C, et al. Mesenchymal stem cell engraftment in lung is enhanced in response to bleomycin exposure and ameliorates its fibrotic effects[J]. Proc Natl Acad Sci U S A, 2003, 100(14):8407-8411.
|
| 12 |
Tögel F, Hu Z, Weiss K, et al. Administered mesenchymal stem cells protect against ischemic acute renal failure through differentiation-independent mechanisms[J].Am J Physiol Renal Physiol, 2005, 289(1):F31-F42.
|
| 13 |
Nilsson B, Teramura Y, Ekdahl KN. The role and regulation of complement activation as part of the thromboinflammation elicited in cell therapies[J]. Mol Immunol, 2014, 61(2):185-190.
|
| 14 |
Ozmen L, Ekdahl KN, Elgue G, et al. Inhibition of thrombin abrogates the instant blood-mediated inflammatory reaction triggered by isolated human islets: possible application of the thrombin inhibitor melagatran in clinical islet transplantation[J]. Diabetes, 2002, 51(6):1779-1784.
|
| 15 |
Gustavson SM, Rajotte RV, Hunkeler D, et al. Islet auto-transplantation into an omental or splenic site results in a normal beta cell but abnormal alpha cell response to mild non-insulin-induced hypoglycemia[J]. Am J Transplant, 2005, 5(10):2368-2377.
|
| 16 |
Moll G, Jitschin R, Von Bahr L, et al. Mesenchymal stromal cells engage complement and complement receptor bearing innate effector cells to modulateimmune responses[J]. PLoS One, 2011, 6(7):e21703.
|
| 17 |
Tatsumi K, Ohashi K, Matsubara Y, et al. Tissue factor triggers procoagulation in transplanted mesenchymal stem cells leading to thromboembolism[J]. Biochem Biophys Res Commun, 2013, 431(2):203-209.
|
| 18 |
Gast A, Tschopp TB, Schmid G, et al. Inhibition of clot-bound and free (fluid-phase thrombin) by a novel synthetic thrombin inhibitor (Ro 46-6240), recombinant hirudin and heparin in human plasma[J]. Blood Coagul Fibrinolysis, 1994, 5(6):879-887.
|
| 19 |
Stephenne X, Nicastro E, Eeckhoudt S, et al. Bivalirudin in combination with heparin to control mesenchymal cell procoagulant activity[J]. PLoS One, 2012, 7(8):e42819.
|
| 20 |
Thirabanjasak D, Tantiwongse K, Thorner PS. Angiomyeloproliferative lesions following autologous stem cell therapy[J].J Am Soc Nephrol, 2010, 21(7):1218-1222.
|